Jury tells Eli Lilly (LLY) to pay Nektar $90M over a broken drug deal

A California jury ruled that Eli Lilly (LLY) broke a good-faith duty in its former partnership on Nektar's eczema drug Rezpeg, awarding $90 million. That is a fraction of the $1 billion Nektar wanted, and Lilly says it will appeal. A modest sum against Lilly's scale, adding to a run of legal pressure.